CN100548321C - Ramulus Et Folium Pithecellobii Lucidi extract is used to prepare the application of Claritin, food and cosmetics - Google Patents
Ramulus Et Folium Pithecellobii Lucidi extract is used to prepare the application of Claritin, food and cosmetics Download PDFInfo
- Publication number
- CN100548321C CN100548321C CNB2004100776593A CN200410077659A CN100548321C CN 100548321 C CN100548321 C CN 100548321C CN B2004100776593 A CNB2004100776593 A CN B2004100776593A CN 200410077659 A CN200410077659 A CN 200410077659A CN 100548321 C CN100548321 C CN 100548321C
- Authority
- CN
- China
- Prior art keywords
- ramulus
- folium pithecellobii
- pithecellobii lucidi
- extract
- allergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 83
- 239000002537 cosmetic Substances 0.000 title claims abstract description 12
- 235000013305 food Nutrition 0.000 title claims description 7
- 229940088529 claritin Drugs 0.000 title description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 title description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 21
- 206010002198 Anaphylactic reaction Diseases 0.000 claims abstract description 18
- 230000036783 anaphylactic response Effects 0.000 claims abstract description 18
- 208000003455 anaphylaxis Diseases 0.000 claims abstract description 18
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 16
- 208000024891 symptom Diseases 0.000 claims abstract description 14
- 208000030961 allergic reaction Diseases 0.000 claims abstract description 13
- 206010012434 Dermatitis allergic Diseases 0.000 claims abstract description 10
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 10
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims abstract description 5
- 206010050639 Allergic pharyngitis Diseases 0.000 claims abstract description 5
- 206010048908 Seasonal allergy Diseases 0.000 claims abstract description 5
- 230000000172 allergic effect Effects 0.000 claims abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 3
- 208000026935 allergic disease Diseases 0.000 claims description 7
- 230000007815 allergy Effects 0.000 claims description 7
- 238000004378 air conditioning Methods 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 16
- 239000002994 raw material Substances 0.000 abstract description 8
- 244000033373 Pithecellobium clypearia Species 0.000 abstract description 5
- 235000013402 health food Nutrition 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 230000003266 anti-allergic effect Effects 0.000 abstract description 4
- 235000013373 food additive Nutrition 0.000 abstract description 4
- 239000002778 food additive Substances 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 2
- 241000596422 Pithecellobium Species 0.000 abstract 1
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 31
- 230000000694 effects Effects 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 240000001307 Myosotis scorpioides Species 0.000 description 13
- 206010030113 Oedema Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000002052 anaphylactic effect Effects 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 206010012442 Dermatitis contact Diseases 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 208000010247 contact dermatitis Diseases 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- -1 some antiseptic Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- ZPLUZNXSYCCJOE-UHFFFAOYSA-N phosphoric acid;propan-2-one Chemical compound CC(C)=O.OP(O)(O)=O ZPLUZNXSYCCJOE-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- GOCCREQJUBABAL-UHFFFAOYSA-N 2,2-dihydroxyacetic acid Chemical compound OC(O)C(O)=O GOCCREQJUBABAL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000244188 Ascaris suum Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241001125929 Trisopterus luscus Species 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000003912 basophilic leucocyte Anatomy 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Providing a kind of is raw material with Ramulus Et Folium Pithecellobii Lucidi (Pithecellobium clypeariaBenth./Archidendron clypearia Jack.Nielsen) and extract, is the antiallergic activity material of the scope of application with pharmaceuticals, food additive, health food and cosmetics.Say that definitely it is that raw material can be used for improving and treat the various clinical symptoms that I～type iv allergic reaction that allergic dermatitis, allergic rhinitis, pollinosis, allergic pharyngitis, anaphylaxis digestive tract reaction, heritability allergic constitution, carpet, Kong Tone, acarid etc. cause and anaphylaxis cause with Ramulus Et Folium Pithecellobii Lucidi and extract that the present invention provides a kind of, can take for a long time, safely, pharmaceuticals, food additive, health food and the cosmetics and the constituent thereof that have no side effect.In addition, the constitutive material that the present invention also points out Ramulus Et Folium Pithecellobii Lucidi extract to can be used as skin preparations for extenal use is used to alleviate and treat allergic dermatitis, also can be used as cosmetic material and is used for daily skin care.
Description
Technical field:
The present invention relates to extracted form natural plant and application.
Background technology:
In recent years, the Epidemiological study anaphylactic disease has the trend that increases year by year, particularly anaphylactoid increase trend such as the allergic dermatitis that is caused by environment reason, allergic rhinitis, pollinosis, allergic pharyngitis are particularly remarkable, become very important social phenomenon.The appearance of its problem is not only because the abuse of the increase year by year of anaphylactogen, atmospheric pollution, food additives, and because the variation of people's dietary habit in recent years.The Therapeutic Method of anaphylactic disease is a basis to eliminate anaphylactogen usually, and then carries out the alternative medicine treatment according to degree, cause and the pathogenesis of clinical symptoms.Anaphylaxis generally is divided into 4 types according to differences such as clinical diseases induced immunoglobulin, relevant cells.I～III type anaphylaxis is characterized in that mainly based on the humoral antibody immunoreation ratio of anaphylaxis appearance is very fast, the immediate hypersensitivity that is otherwise known as reaction disease (immediate type allergy); Type iv allergic reaction is the immunoreation based on lymphocyte, the delayed that is otherwise known as clinically anaphylaxis (delayed type allergy).
Diseases such as allergic rhinitis, bronchial asthma and urticaria belong to type i allergic reaction clinically.Type i allergic reaction act as medium with immunoglobulin [Immunoglobulin E (IgE)] antibody, by mastocyte (mast cell) and basophil (basophilic leucocyte), intracellular histamine (histamine), leukotriene [leukotrienes (LT)] etc. is chemical mediator (chemical mediator), and then stimulation vasodilation, increase vascular permeability, promote bronchial smooth muscle to shrink, improve excessive organism stress such as terminal neuroinduction.Therefore, to the treatment of I type anaphylactic disease, mainly use antihistaminic clinically and mastocyte discharged chemical mediator to have the active Claritin of inhibition.But Claritins such as antihistaminic are most in clinical use side effect such as sleepy, thirsty, gastro-intestinal digestion system damage to occur, takes for a long time also to have certain clinical safety problem.
Type iv allergic reaction is the delayed hypersensitivity reaction relevant with the T cell.Be antigenic information to be provided and to promote induction (sensitization) to the T cell by immune presenting cells such as islet cells, macrophages, the T cell discharges various cytokines subsequently, start eosinophil leucocyte (eosinophilic leukocyte), macrophage (macrophage), the result causes the delayed inflammatory reaction.Anaphylaxis contact dermatitis is actually a kind of clinical representative symptom of type iv allergic reaction.Clinically the treatment of IV type anaphylactic disease is generally used the sterols external preparation and strengthened the therapy that life is instructed.It is plain that the pharmacological action of sterols preparation is that suppressor T cell and macrophage (macrophage) secretory cell are situated between, and the treatment of eczema is truly had certain clinical effectiveness.But a large amount of or long-time use will cause adrenal cortex underactivity, side effect such as local skin atrophy, flushing, telangiectasis occur.In addition, although the sterols preparation usually uses as the antihistamine preparation clinically, its antiallergic effect also only is to alleviate skin itching (itching) to a certain extent.Allergic skin diseases, particularly allergic dermatitis increase clinically year by year in recent years.The origin cause of formation of relevant allergic dermatitis also has various theories for a long time.In recent years, based on the feature of pathology and clinical symptoms, it should be noted that allergic dermatitis is not to result from type i allergic reaction, and very big dependency is arranged on the pathology cause with type iv allergic reaction.
Up to now, people also pay attention to development and exploitation to its medicine when the Pathophysiology of anaphylactic disease is analyzed.But the antiallergic preparation majority of clinical practice has side effect, also only is confined to temporary alleviation on effect, and can not fundamentally improves allergic constitution.Life style that modern society brings and the variation on the environment make anaphylactic disease demonstrate the trend of increase year by year.From healthy and living habit angle, a kind of can take for a long time and safe being used to improves or treat the health food of anaphylactic disease or the development of pharmaceuticals is expected by people.Certainly, from the prevention viewpoint, can be used as the anti-allergic agent of daily beverage or can be used as the anti-allergic agent of daily cosmetics additive even more ideal.
Chinese medicine Ramulus Et Folium Pithecellobii Lucidi (Folium Pithecellobii) is dry sprig and the leaf of pulse family Ramulus Et Folium Pithecellobii Lucidi platymiscium Ramulus Et Folium Pithecellobii Lucidi (Pithecellobium clypearia Benth./Archidendronclypearia Jack.Nielsen).Ramulus Et Folium Pithecellobii Lucidi is an arbor, is distributed in Tropical Asia.Ramulus Et Folium Pithecellobii Lucidi (Pithecellobium clypearia Benth./Archidendron clypearia Jack.Nielsen) has another name called bib tree, chicken three-tree etc., and its leaf, seed and fruit all can be used as medicine, and among the peoplely is used to the treatment of burning, scalding.Commercially available Ramulus Et Folium Pithecellobii Lucidi antiimflammatory tablet and antiphlogistic capsule are that raw material is made with the Ramulus Et Folium Pithecellobii Lucidi water extract.Be used for the treatment of diseases such as upper respiratory tract infection, acute pharyngolaryngitis, acute tonsillitis, acute enteritis clinically, also be used for the treatment of bacillary dysentery.Also few about the pharmacologically active and the The Chemical Constituents of plant Ramulus Et Folium Pithecellobii Lucidi both at home and abroad, it is generally acknowledged that gallic acid is active component (Wan An phoenix of Ramulus Et Folium Pithecellobii Lucidi anti-inflammation, Zhou Lang: the HPLC method is measured the content of gallic acid in the Ramulus Et Folium Pithecellobii Lucidi antiimflammatory tablet. Chinese crude drug .23:708-708,2000.).
In recent years, people are concerned about the research of natural materials physiologically active very much, to traditional Chinese herbal medicine and biological function that natural plant kind has special concern especially.The history in existing thousands of years of tradition Chinese herbal medicine, these traditional Chinese herbal medicine to all regulatory functions of health since ancient times early with known: existing reports such as the anti-inflammatory effect of Ramulus Et Folium Pithecellobii Lucidi, antibacterial action for example.But still there is not the discussion of any application facet for the antiallergic system of Ramulus Et Folium Pithecellobii Lucidi.
Summary of the invention:
It is raw material that goal of the invention of the present invention is to provide with Ramulus Et Folium Pithecellobii Lucidi and Ramulus Et Folium Pithecellobii Lucidi extract, prepare a kind of safe, have no side effect be used for prevention and irritated, the allergic dermatitis of treatment, the medicine of the various clinical symptoms that I～type iv allergic reaction that allergic rhinitis, pollinosis, allergic pharyngitis, anaphylaxis digestive tract reaction, heritability allergic constitution, carpet, Kong Tone, acarid etc. cause and anaphylaxis cause.Described medicine comprises the Ramulus Et Folium Pithecellobii Lucidi and the Ramulus Et Folium Pithecellobii Lucidi extract of dose therapeutically effective, and pharmaceutically acceptable pharmaceutical carrier.The prevention of the clinical symptoms that this medicine particularly causes I～type iv allergic reaction, treatment effectively for example have to allergic rhinitis, allergic pharyngitis and allergic dermatitis and by the caused clinical symptoms of these anaphylaxiss and suppress or alleviate effect.
It is raw material that another goal of the invention of the present invention is to provide with Ramulus Et Folium Pithecellobii Lucidi and Ramulus Et Folium Pithecellobii Lucidi extract, and preparation is used for prevention, it is irritated to improve, and can take for a long time, the purposes of safe, the health food, food and the food additive that have no side effect.The daily food that contains Ramulus Et Folium Pithecellobii Lucidi and Ramulus Et Folium Pithecellobii Lucidi extract of taking can alleviate the symptoms such as pharyngitis, pollinosis symptom and cough that reaction causes with Polyglucan.
It is raw material that another goal of the invention of the present invention is to provide with Ramulus Et Folium Pithecellobii Lucidi and Ramulus Et Folium Pithecellobii Lucidi extract, and preparation is used to alleviate and treats anaphylactoid safe, the skin preparations for extenal use that has no side effect such as some allergic dermatitis or the purposes of cosmetics.This skin preparations for extenal use or cosmetics can be used for daily skin care.
Ramulus Et Folium Pithecellobii Lucidi of the present invention and Ramulus Et Folium Pithecellobii Lucidi extract are to adopt one or two or more kinds any mixed solvent of lower alcohols such as hot water or water and methanol, ethanol, acetone isopolarity solvent to extract.
Because commercially available Ramulus Et Folium Pithecellobii Lucidi antiinflammatory is many to be raw material with the water extract, so generally get final product with water extraction, also the lower alcohols of available variable concentrations, acetone isopolarity solvent or any mixed solvent extract.When extracting, along with the interpolation of alcohol, the extraction of active ingredients rate can increase to some extent in the Ramulus Et Folium Pithecellobii Lucidi.Although the water extraction effect, also can reach with alcohol extraction and follow the example of suitable result along with water temperature increase and the prolongation of extraction time not as with the solvent extraction of having added certain alcohol.Therefore, for extraction of active ingredients in the Ramulus Et Folium Pithecellobii Lucidi, said extracted method and combination in any thereof all can obtain extract of the present invention.
In view of Ramulus Et Folium Pithecellobii Lucidi extract is to develop as final products with medicament, health food or cosmetics, select water or aquiferous ethanol to be advisable so consider to extract solvent from safety perspective as far as possible.The monkey ring does not have specific limited with the ratio of solvent during extraction, but the ratio of general Ramulus Et Folium Pithecellobii Lucidi and solvent is advisable with 1: 1～50 scopes.The present invention does not have specific limited to extracting temperature, and is all applicable to the solvent boiling point scope from room temperature.Certainly room temperature, normal pressure and in the solvent boiling point scope, extract ideal.Extraction time, scope could from 10 seconds to 24 hours.When extracting Ramulus Et Folium Pithecellobii Lucidi extract, also can in solvent, add sodium bicarbonate, SODIUM ASCORBATE materials such as (sodium ascorbate) as required.These extracting method can not influence the biological activity that Ramulus Et Folium Pithecellobii Lucidi had originally.
The use amount of Ramulus Et Folium Pithecellobii Lucidi provided by the invention and Ramulus Et Folium Pithecellobii Lucidi extract is generally at 0.01% to 50% (W/W), because beverage interpolation concentration is generally comparatively suitable in 0.01% to 50% (W/W) scope usually.In this concentration range, Ramulus Et Folium Pithecellobii Lucidi extract is suitable for directly taking, and is accepted by consumer easily.Certainly, as the increase along with addition of the Ramulus Et Folium Pithecellobii Lucidi extract of additive, pained sensation may appear.Its solution can require according to the psychology of market demand and consumer to change dosage form, for example uses dosage forms such as tablet, granule, capsule.Low concentration Ramulus Et Folium Pithecellobii Lucidi extract solution can be used as daily beverage and offers consumer.
Ramulus Et Folium Pithecellobii Lucidi provided by the invention and Ramulus Et Folium Pithecellobii Lucidi extract can be put on market by multiple peroral dosage form, are used to prevent, improve and treat the various clinical symptoms that anaphylaxis and anaphylaxis cause.Certainly, Ramulus Et Folium Pithecellobii Lucidi and Ramulus Et Folium Pithecellobii Lucidi extract also can combine preparationization then with pharmaceutical carriers such as excipient commonly used.Also can add preparation additives such as some antiseptic, antioxidant (antioxidant), coloring agent, sweeting agent in case of necessity.
Relatively Shi Yi Ramulus Et Folium Pithecellobii Lucidi and Ramulus Et Folium Pithecellobii Lucidi extract excipient generally consider to have lactose, white sugar, D-mannitol, starch, crystalline cellulose etc.Lubricant generally should adopt magnesium stearate, calcium stearate, Pulvis Talci etc.Solvent uses Purified Water, ethanol, propylene glycol etc. usually.Antiseptic generally adopts methaform, benzylalcohol, dihydroxy acetic acid etc.Antioxidant is more suitable with sulphite, ascorbic acid etc. usually.
Ramulus Et Folium Pithecellobii Lucidi provided by the invention and Ramulus Et Folium Pithecellobii Lucidi extract, can its prototype, extract or powder add to be used in the goods oral.Ramulus Et Folium Pithecellobii Lucidi extract also can combine with other beverage raw material and make certain beverage product, as Ramulus Et Folium Pithecellobii Lucidi beverage, carbonated beverage, fruit drink, lactobacillus beverage, sports drink, soyabean milk etc.Ramulus Et Folium Pithecellobii Lucidi extract food it is also conceivable that daily breads such as making cookies, chocolate-like, confection class, chewing gum class, snack class, fruit jelly snack categories, bread, bean curd, yoghourt.
Ramulus Et Folium Pithecellobii Lucidi that provides among the present invention and Ramulus Et Folium Pithecellobii Lucidi extract also can prototypes, aqueous solution dilution back uses as skin preparations for extenal use.Can certainly make certain preparation by combining, the consumption in cosmetics, pharmaceuticals market is provided as dosage forms such as aerosol, liquid preparation, extract, suspensoid, Emulsion, ointment, semifluid preparation, liniment, lotions with pharmaceutical carrier.
The invention provides Ramulus Et Folium Pithecellobii Lucidi and Ramulus Et Folium Pithecellobii Lucidi extract is proved by following experiment as inflammation, prevention hypersensitive, improvement and therapeutic agent.In the pharmacological evaluation of using the irritated animal model of IV type, Ramulus Et Folium Pithecellobii Lucidi extract reaches 50mg/kg when above at dispensing dosage, promptly demonstrates the effect of effective inhibition edema.The dosage of Ramulus Et Folium Pithecellobii Lucidi and Ramulus Et Folium Pithecellobii Lucidi extract among the present invention can be regulated according to application person's conditions such as health status, age, sex and body weight.Adult's average weight is as in 60Kg, Ramulus Et Folium Pithecellobii Lucidi and Ramulus Et Folium Pithecellobii Lucidi extract day oral dose generally can consider in 3g to 10g scope part vic.Certainly there are not problems such as side effect more than the 10g yet.
The present invention is with 2, and 4-dinitrofluorobenzene (DNFB) brings out the test model of mouse ear contact dermatitis as the type iv allergic reaction animal, estimates Ramulus Et Folium Pithecellobii Lucidi and Ramulus Et Folium Pithecellobii Lucidi extract and contained active component thereof the inhibition effect to type iv allergic reaction.The result shows that Ramulus Et Folium Pithecellobii Lucidi extract shows significant therapeutic activity on the statistics to the mouse ear contact dermatitis that DNFB brings out.In addition, the present invention also finds mice delayed foot anaphylaxis edema tool that Ramulus Et Folium Pithecellobii Lucidi extract brings out sheep redblood cells (SRBC) effect that has some improvement.Confirm that based on The above results the present invention sets up.
The specific embodiment:
The present invention can be elaborated by following examples, but is not limited only to following examples.
Embodiment one: the preparation of Ramulus Et Folium Pithecellobii Lucidi extract
Get Ramulus Et Folium Pithecellobii Lucidi dried leaves 100g, add 90 ℃ of hot water 2000ml lixiviate 5 minutes.Extracting solution in 1000rpm, centrifugalize in 5 minutes, reclaims the supernatant lyophilization with filtrate after gauze filters.The above-mentioned lyophilization extract of Ramulus Et Folium Pithecellobii Lucidi leaf is used for the following example of the present invention.
Embodiment two: Ramulus Et Folium Pithecellobii Lucidi extract causes the improvement of mouse ear contact dermatitis to DNFB
Effect
Experimental technique reference literature (Claman HN.and Jaffee BD.:Desensitization of contact allergy to DNFB in mice.I.Description of a model system.J.Immunol., 131:2682-2686,1983.), use male 7 age in week Kunming mouse, experimentize after raising a week.10/group of mice, via 2 of back subcutaneous injection 1.5%, (Merck) alcoholic solution 100 μ l make it enhanced sensitivity (sensitization) as antigen to 4-DNFB for 1-fluor-2,4-dinitro-benzene:DNFB.Injection 2,4-DNFB is enhanced sensitivity (sensitization) establishment after 5 days, is coated with 1%2 on the 6th day on mouse right ear, and the 4-DNFB-olive oil solution is attacked as antigen, makes mice produce ear edge contact dermatitis.After 24 hours, take off the ear edge, measure ear edge/8mm weight difference and comparison edema degree with diameter 8mm card punch.Ramulus Et Folium Pithecellobii Lucidi extract is enhanced sensitivity (sensitization) the previous day to 2, and 4-DNFB attacks oral administration on continuous 7 days of the same day.Matched group is fed with the volume distilled water.The result does the calibrating of the significance difference opposite sex with student t-test, and is as shown in table 1.With distilled water matched group 2,4-DNFB brings out ear edge edema weight and compares, and continuous 7 days oral administrations of Ramulus Et Folium Pithecellobii Lucidi extract demonstrate certain inhibition effect to mouse ear edge edema, and are the dosage dependence.
Table one: Ramulus Et Folium Pithecellobii Lucidi extract brings out the influence of mouse ear edge contact dermatitis to DNFB
| Group | Number of animals | Weight (mg/8mm ear edge) |
| Normal mouse (DNFB) | 10 | 17.9±0.4 |
| H 2The O matched group (+DNFB) | 10 | 31.8±2.1 |
| Ramulus Et Folium Pithecellobii Lucidi extract 50mg/kg (+DNFB) | 10 | 27.2±1.6 |
| Ramulus Et Folium Pithecellobii Lucidi extract 100mg/kg (+DNFB) | 10 | 23.6±0.9(p＜0.05) |
| Ramulus Et Folium Pithecellobii Lucidi extract 200mg/kg (+DNFB) | 10 | 21.8±1.3(p＜0.05) |
Embodiment three: Ramulus Et Folium Pithecellobii Lucidi extract oozes DNFB Lure development mouse ear contact dermatitis blood vessel
Leakage Xing Kang Jin improves effect
Two described with embodiment, 1%2, the 4-DNFB-olive oil solution as antigen attack 23 hours, press 0.1ml/10g body weight dosage and in mouse tail vein, inject 1% Ai Wensilan (Evans blue) normal saline solution.Injection Ai Wensilan normal saline one as a child after, take off the ear edge with diameter 8mm card punch, with reference to katayama method (A new method forextraction of extravasated dye in the skin and the influenceof fasting stress on passive cutaneous anaphylaxis in guineapigs and rats.Microbiol.Immunol., 22:89-101,1978.), the ear edge is put into the 1N KOH aqueous solution of 1ml, 37 ℃ are soaked after 24 hours down, add 9ml0.6N phosphoric acid-acetone (5: 13) solution, fully stir back centrifugalize (3000rpm/15 minute).Take out supernatant and measure absorbance in 620nm wavelength place, calculate the Ai Wensilan amount as the vascular permeability index, analytical judgment edema situation.Ramulus Et Folium Pithecellobii Lucidi extract is enhanced sensitivity the previous day to 2, and 4-DNFB attacks oral administration on continuous 7 days of the same day.Matched group is fed with the volume distilled water.The result does the calibrating of the significance difference opposite sex with student t-test.Experimental result is as shown in table 2, and with distilled water matched group 2,4-DNFB brings out ear edge vascular leakage and compares, and continuous 7 days oral administrations of Ramulus Et Folium Pithecellobii Lucidi extract demonstrate certain inhibition effect to mouse ear edge vascular leakage, and are the dosage dependence.
Table two: Ramulus Et Folium Pithecellobii Lucidi extract brings out the hyperfunction inhibition effect of mouse ear edge vascular leakage to DNFB
| Group | Number of animals | Ai Wensilan seepage (leakage) (μ g/8mm ear edge) |
| Normal mouse (DNFB) | 10 | - |
| H 2The O matched group (+DNFB) | 10 | 5.79±0.72 |
| Ramulus Et Folium Pithecellobii Lucidi extract 50mg/kg (+DNFB) | 10 | 4.48±1.02 |
| Ramulus Et Folium Pithecellobii Lucidi extract 100mg/kg (+DNFB) | 10 | 4.06±0.69(p＜0.05) |
| Ramulus Et Folium Pithecellobii Lucidi extract 200mg/kg (+DNFB) | 10 | 2.68±1.40(p＜0.01) |
Embodiment four: Ramulus Et Folium Pithecellobii Lucidi extract is to sheep red blood cells (SRBC) Lure development
Mice delayed foot anaphylaxis Fu Swollen improves effect
Reference literature method (Lagrange, P.H., Mackaness, G.B.andMiller, T.E.:Influence of dose and route of antigen injectionon the immunological induction of cells.J.Exp.Med.139:528-542,1974.), use the bright Seed mice of male 7 week elder brothers in age, experimentize after raising a week.10/group of mice, the cotton sheep erythrocyte of right hind vola subcutaneous injection (SRBC) 10
7Cells/25 μ l is as antigen enhanced sensitivity (sensitization).After 4 days, the left hind vola is subcutaneous with 10
8Cells/25 μ lSRBC is as antigen injection attack once more.Antigen is attacked and is used special gauge (gauge) to measure vola thickness after 24 hours, calculates the edema rate.Ramulus Et Folium Pithecellobii Lucidi extract in enhanced sensitivity (sensitization) the previous day to attacking oral administration on continuous 5 days of the same day with SRBC.Matched group is given with the capacity distilled water.Experimental result is done the significant difference calibrating with studentt-test.As shown in table 2, bring out mice delayed vola edema with distilled water matched group SRBC and compare, continuous 5 days oral administrations of Ramulus Et Folium Pithecellobii Lucidi extract demonstrate certain dosage interdependence and suppress effect.
Table three: Ramulus Et Folium Pithecellobii Lucidi extract brings out the mice delayed to SRBC
FootThe inhibition effect of palm edema
| Group | Number of animals | Vola edema (mm) |
| Normal mouse (SRBC) | 10 | 3.26±0.24 |
| H 2The O matched group (+SRBC) | 10 | 3.62±0.21 |
| Ramulus Et Folium Pithecellobii Lucidi extract 50mg/kg (+SRBC) | 10 | 3.42±0.15(p＜0.05) |
| Ramulus Et Folium Pithecellobii Lucidi extract 100mg/kg (+SRBC) | 10 | 3.32±0.23(p＜0.01) |
| Ramulus Et Folium Pithecellobii Lucidi extract 200mg/kg (+SRBC) | 10 | 3.33±0.09(p＜0.005) |
Embodiment five: Ramulus Et Folium Pithecellobii Lucidi extract is to passive cutaneous anaphylaxis (PCA)
Reaction improve effect
Reference literature method (Tada T.and Okumura K.:Regulation ofhomocytotropic antibody formation in the rat.J.Immunol., 106:1002-1011,1971.) use pig return the worm extract in conjunction with the dinitrophenyl base, make antigen Wu Quality dinitrophenylated Ascaris suum extract (DNP-As).Antiserum is with Tada ﹠amp; The above-mentioned literature method of Okumura is made immune rat serum.The anti-ying reference literature of mouse ear edge PCA method (Inagaki N., Goto S., Nagai H.and Koda A.:Mouse ear PCA as a model for evaluatingantianaphylactic agents.Int.Arch.Allergy Immunol., 74:91-92,1984.) use the bright Seed mice of male 7 week elder brothers in age, experimentize after raising a week.10 of mices/group, mouse ear edge subcutaneous injection 10 μ l with the anti-DNP-As serum of 1000 times of uncommon Taishaku of Sheng Li salt water, enhanced sensitivity 48 Xiao Time Hous, in mouse tail vein, inject the anti-ying of 0.5%Evans blue Sheng Li salt aqueous solution, Lure development PCR that contains 0.25mg DNP-As of 0.25ml/head.After the injection one as a child, take off the ear edge, measure ear edge/8mm weight difference and comparison edema degree with diameter 8mm card punch.And is with reference to katayama method (A new method for extraction of extravasated dye in the skinand the influence of fasting stress on passive cutaneousanaphylaxis in guinea pigs and rats.Microbiol.Immunol., 22:89-101,1978.), the ear edge is put into the 1N KOH aqueous solution of 1ml, 37 ℃ are soaked after 24 hours down, add 9ml 0.6N phosphoric acid-acetone (5: 13) solution, fully stir back centrifugalize (3000rpm/15 minute).Take out supernatant and measure absorbance in 620nm wavelength place, calculate the Ai Wensilan amount as the vascular permeability index, analytical judgment edema situation.Ramulus Et Folium Pithecellobii Lucidi extract is attacked oral administration on continuous 4 days of the same day to DNP-As antigen in the antiserum enhanced sensitivity the previous day.Matched group is fed with the volume distilled water.Experimental result such as table 4 shown in 5, bring out ear edge edema weight with distilled water matched group PCR and vascular leakage is compared, and continuous 4 days oral administrations of Ramulus Et Folium Pithecellobii Lucidi extract demonstrate certain inhibition effect, and are the dosage dependence.
Table four: Ramulus Et Folium Pithecellobii Lucidi extract brings out the influence of mouse ear Yuan Fu Swollen to the anti-ying of PCA
| Group | Number of animals | Weight (mg/8mm ear edge) |
| Normal mouse (DNFB) | 10 | 16.5±1.4 |
| H 2The O matched group (+DNFB) | 10 | 27.4±2.9 |
| Ramulus Et Folium Pithecellobii Lucidi extract 50mg/kg (+DNFB) | 10 | 24.6±1.3(p＜0.05) |
| Ramulus Et Folium Pithecellobii Lucidi extract 100mg/kg (+DNFB) | 10 | 21.2±3.9(p＜0.001) |
| Ramulus Et Folium Pithecellobii Lucidi extract 200mg/kg (+DNFB) | 10 | 19.5±2.1(p＜0.001) |
Table five: Ramulus Et Folium Pithecellobii Lucidi extract brings out the inhibition effect of mouse ear edge vascular leakage Kang Jin to the anti-ying of PCA
| Group | Number of animals | Ai Wensilan seepage (leakage) (μ g/8mm ear edge) |
| Normal mouse (DNFB) | 10 | - |
| H 2The O matched group (+DNFB) | 10 | 4.17±1.64 |
| Ramulus Et Folium Pithecellobii Lucidi extract 50mg/kg (+DNFB) | 10 | 3.83±1.52 |
| Ramulus Et Folium Pithecellobii Lucidi extract 100mg/kg (+DNFB) | 10 | 3.42±0.50 |
| Ramulus Et Folium Pithecellobii Lucidi extract 200mg/kg (+DNFB) | 10 | 2.94±0.32(p＜0.05) |
Claims (6)
1. Ramulus Et Folium Pithecellobii Lucidi extract is used to prepare treatment or improves allergy and the purposes of the medicine of the irritated clinical symptoms that causes.
2. Ramulus Et Folium Pithecellobii Lucidi extract is used to prepare treatment or improves allergy and the purposes of the food of the irritated clinical symptoms that causes.
3. Ramulus Et Folium Pithecellobii Lucidi extract is used to prepare treatment or improves allergy and the purposes of the cosmetics of the irritated clinical symptoms that causes.
4. according to the purposes of claim 1 or 2 or 3 described Ramulus Et Folium Pithecellobii Lucidi extracts, it is characterized in that: described Ramulus Et Folium Pithecellobii Lucidi extract is used to prepare and improves and medicine or the food or the cosmetics of the various clinical symptoms that I～type iv allergic reaction that treatment allergic dermatitis, allergic rhinitis, pollinosis, allergic pharyngitis, anaphylaxis digestive tract reaction, heritability allergic constitution, carpet, air-conditioning, acarid cause and anaphylaxis cause.
5. according to the purposes of claim 1 or 2 or 3 described Ramulus Et Folium Pithecellobii Lucidi extracts, it is characterized in that: described Ramulus Et Folium Pithecellobii Lucidi extract adopts polar solvent to extract.
6. according to the purposes of claim 1 or 2 or 3 described Ramulus Et Folium Pithecellobii Lucidi extracts, it is characterized in that: the oral dose of described Ramulus Et Folium Pithecellobii Lucidi extract, the adult is 3～10g every day.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100776593A CN100548321C (en) | 2004-12-29 | 2004-12-29 | Ramulus Et Folium Pithecellobii Lucidi extract is used to prepare the application of Claritin, food and cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100776593A CN100548321C (en) | 2004-12-29 | 2004-12-29 | Ramulus Et Folium Pithecellobii Lucidi extract is used to prepare the application of Claritin, food and cosmetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1795888A CN1795888A (en) | 2006-07-05 |
| CN100548321C true CN100548321C (en) | 2009-10-14 |
Family
ID=36817343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100776593A Expired - Fee Related CN100548321C (en) | 2004-12-29 | 2004-12-29 | Ramulus Et Folium Pithecellobii Lucidi extract is used to prepare the application of Claritin, food and cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100548321C (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10195136B2 (en) * | 2011-08-24 | 2019-02-05 | Avon Products, Inc. | Collagen and elastin stimulating compositions and uses thereof |
| TW201422246A (en) * | 2012-12-11 | 2014-06-16 | Avon Prod Inc | Method of improving aging appearance of skin by modulation of WIPI-1 |
| CN103330664B (en) * | 2013-06-08 | 2015-10-07 | 南方医科大学 | A kind of application of Chinese medicine extract at hair cosmetic with anti-dandruff function |
| CN103385912B (en) * | 2013-07-24 | 2015-06-17 | 中山大学 | Pithecellobium clypearia extracts and application of extract in preparation of medicines for treating methicillin-resistant staphylococcus aureus |
| CN103800580A (en) * | 2013-12-27 | 2014-05-21 | 芜湖乐锐思信息咨询有限公司 | Traditional Chinese medicinal prescription for treating adenoidal hypertrophy and preparation method thereof |
| CN103720957A (en) * | 2013-12-31 | 2014-04-16 | 芜湖乐锐思信息咨询有限公司 | Chinese medicinal formula for treating adenoidal hypertrophy and preparation method thereof |
| CN104974018B (en) * | 2015-06-15 | 2016-08-24 | 沈阳药科大学 | Compound extracted from Chinese medicine Ramulus Et Folium Pithecellobii Lucidi and application thereof |
| CN105998153B (en) * | 2016-05-10 | 2019-09-17 | 中山大学 | Ramulus Et Folium Pithecellobii Lucidi extract is preparing the application in anti-ESBLs-producing bacteria Escherichia coli drug |
| CN111012819A (en) * | 2019-12-31 | 2020-04-17 | 江西杏林白马药业有限公司 | A nanometer preparation of Pithecellobium clypearia extract and its preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364518A (en) * | 2001-01-17 | 2002-08-21 | 杨孟君 | Nano pittecellobium clypearia Benth anti-imflammatory medicine and its preparing method |
-
2004
- 2004-12-29 CN CNB2004100776593A patent/CN100548321C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364518A (en) * | 2001-01-17 | 2002-08-21 | 杨孟君 | Nano pittecellobium clypearia Benth anti-imflammatory medicine and its preparing method |
Non-Patent Citations (1)
| Title |
|---|
| 药品标准. 185. 1992 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1795888A (en) | 2006-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6416795B1 (en) | Herbal extract composition for stress prevention and treatment | |
| CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
| CN101347395A (en) | Chinese medicine floral water for preventing and treating bite by mosquitos | |
| KR20150086982A (en) | Composition comprising Polygala tenuifolia extract for preventing or treating atopic dermatitis | |
| US20030215530A1 (en) | Antiallergic agent, anti-inflammatory agent, anti-atopic dermatitis agent and antipsoriatic agent | |
| CN100548321C (en) | Ramulus Et Folium Pithecellobii Lucidi extract is used to prepare the application of Claritin, food and cosmetics | |
| WO2019132625A1 (en) | Composition for preventing, improving or treating atopic dermatitis containing mixed herbal extract as active ingredient | |
| KR101826737B1 (en) | A composition containing herbs extract, and manufacturing method of the same | |
| CN101244095A (en) | New purpose of durio zibethinus L. shell extract | |
| KR101270736B1 (en) | A composition comprising extract from herbal for improving pruritus | |
| KR101432746B1 (en) | Mixture extract of yacon(Smallanthus sonchifolius), Torilis japonica and Acorus gramineus, health food composition and cosmetic composition for preventing or improving benign prostatic hyperplasia or alopecia containing the same | |
| Ross | Sleep disorders: a single dose administration of valerian/hops fluid extract (dormeasan) is found to be effective in improving sleep | |
| CN110973625A (en) | Liver-protecting and sobering-up composition based on fructus cannabis and preparation method and application thereof | |
| WO2018035706A1 (en) | Traditional chinese medicine preparation for atopic dermatitis, preparation method therefor and use thereof | |
| KR101865142B1 (en) | Pharmaceutical composition containing combination extract of Spiraea prunifolia, Pyrus pyrifolia and Geum japonicum for prevention and treatment of allergic diease | |
| KR101160249B1 (en) | Pharmaceutical Composite Comprising Soft-Shelled Turtle For Improvement or Treatment of Skin Disease | |
| WO2020080696A1 (en) | Composition comprising plant extract of genus fraxinus as active ingredient for preventing, alleviating, or treating sleep disorders | |
| Yadav et al. | Experimental evidences showing nutritional and medicinal property of Carica papaya plant | |
| CN1297299C (en) | Application of cocoa extract in preparing medication of anti irritability and anti inflammation, foodstuff and cosmetic | |
| KR101658429B1 (en) | Composition for preventing or improving atopic dermatitis comprising supercritical fluid extract of persimmon peel as effective component | |
| CN109568182B (en) | Tea oil soothing cream for children | |
| CN114931214B (en) | Chinese herbal medicine composition for improving hearing impairment and preparation method and application thereof | |
| CN112843155B (en) | Composition suitable for puerpera and used for removing freckles and relieving lumbago | |
| CN113181205B (en) | Pharmaceutical composition comprising NMN and use thereof | |
| KR102001026B1 (en) | A composition for hepatoprotective or relieving hangover comprising herbal extracts complex and l- aspartic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070810 Address after: Six floor, Longde building, 337 Tianhe Road, Guangzhou, China Applicant after: Laitai Pharmacy Co., Ltd., Guangzhou Address before: Guangdong, Conghua province Guangzhou economic and Technological Development Zone, No. 16 from broad road Applicant before: Guangzhou LifeTech Pharmaceutical Co., Ltd. |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Wu Rongrong Document name: Notice of conformity |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU LIFETECH PHARMACEUTICALS LTD. Free format text: FORMER OWNER: GUANGZHOU LIFETECH PHARMACEUTICAL CO., LTD. Effective date: 20101020 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510620 6/F, LONGDE BUILDING, NO.337, TIANHE ROAD, GUANGZHOU CITY TO: 510990 NO.16, GUANGCONG AVENUE, GUANGDONG CONGHUA ECONOMIC DEVELOPMENT ZONE, CONGHUA, GUANGZHOU CITY, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101020 Address after: 510990, Guangdong, Conghua Guangdong Conghua Guangzhou Economic Development Zone, No. 16 from broad road Patentee after: Guangzhou LifeTech Pharmaceutical Co., Ltd. Address before: 510620, six building, Longde building, 337 Tianhe Road, Guangzhou Patentee before: Laitai Pharmacy Co., Ltd., Guangzhou |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091014 Termination date: 20201229 |